Towerview LLC Purchases 65,000 Shares of Alumis Inc. $ALMS

Towerview LLC lifted its stake in Alumis Inc. (NASDAQ:ALMS) by 15.1% during the 2nd quarter, Holdings Channel reports. The firm owned 495,000 shares of the company’s stock after acquiring an additional 65,000 shares during the period. Alumis makes up 1.1% of Towerview LLC’s holdings, making the stock its 11th biggest holding. Towerview LLC’s holdings in Alumis were worth $1,485,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Tybourne Capital Management HK Ltd. acquired a new position in shares of Alumis during the 2nd quarter worth about $4,198,000. Credit Industriel ET Commercial grew its holdings in Alumis by 178.8% during the second quarter. Credit Industriel ET Commercial now owns 387,002 shares of the company’s stock valued at $1,161,000 after purchasing an additional 248,202 shares during the period. Blair William & Co. IL acquired a new position in Alumis during the second quarter valued at approximately $200,000. BML Capital Management LLC bought a new stake in Alumis in the first quarter valued at approximately $305,000. Finally, Invesco Ltd. acquired a new stake in Alumis in the first quarter worth $164,000.

Alumis Price Performance

Shares of NASDAQ:ALMS opened at $4.72 on Friday. The company has a market capitalization of $491.18 million, a P/E ratio of -1.00 and a beta of -1.33. The business’s 50 day simple moving average is $4.43 and its 200 day simple moving average is $4.16. Alumis Inc. has a 1 year low of $2.76 and a 1 year high of $12.30.

Alumis (NASDAQ:ALMS) last posted its earnings results on Wednesday, August 13th. The company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.06). The firm had revenue of $2.67 million for the quarter, compared to analysts’ expectations of $1.80 million. On average, sell-side analysts anticipate that Alumis Inc. will post -8.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ALMS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alumis in a research note on Wednesday, October 8th. Morgan Stanley reduced their price target on Alumis from $23.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, August 15th. HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of Alumis in a research note on Thursday, August 14th. Wall Street Zen upgraded shares of Alumis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, Wells Fargo & Company began coverage on shares of Alumis in a research note on Friday, July 25th. They issued an “overweight” rating and a $17.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $19.20.

Alumis Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.